ValGenesis, Inc. Announces Integration of ValGenesis Solution with Microsoft SharePoint Server

ValGenesis, Inc. Announces Integration of ValGenesis Solution with Microsoft SharePoint Server 
  

FREMONT, Calif., Aug. 11 /PRNewswire/ -- ValGenesis, Inc., a leading provider of Validation Lifecycle Management solutions, announces the worldwide availability of Microsoft SharePoint Server integration with the latest version of ValGenesis 2.0 for increased enterprise productivity specifically for regulated Pharmaceuticals, Biotech and Medical Devices companies. This offering will seamlessly provide global access, retrieval and storage of corporate validation data and documents generated by ValGenesis within Microsoft SharePoint Server. Companies will be able to keep all the business-critical and compliance data in one central location leveraging real-time reporting and robust search functionality of Microsoft SharePoint Server. ValGenesis Integration with SharePoint follows a familiar usability-driven scenario resulting in an end-to-end secured, 100% paperless, validation lifecycle management solution provided by these two complementary technologies.


"Many Life Sciences companies have standardized on Microsoft SharePoint Server for document management and want the flexibility to leverage this investment. ValGenesis continues to offer state of the art ValGenesis software and now allows customers to use Microsoft SharePoint Server to provide validation data and documents throughout the enterprise through this integration. ValGenesis offers SharePoint users strengthened return on investment and additional usability, functionality and productivity," said Siva Samy, Ph.D., ValGenesis Chief Product Strategist.


About ValGenesis


ValGenesis offers an innovative software platform that serves as the foundation for compliance-based validation life cycle management in regulated companies. ValGenesis is the first Enterprise application to automate the validation lifecycle of GxP systems and to provide 360-degree visibility to the corporate validation process. ValGenesis is designed to fully conform to FDA 21 CFR Part 11 compliance requirements. Through an industry peer review committee, the Parenteral Drug Association (PDA), awarded ValGenesis the prestigious New Innovative Technology award.

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.